+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anti-Hypertensive Drugs Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5734965
The anti-hypertensive drugs market size has grown steadily in recent years. It will grow from $35.8 billion in 2023 to $36.7 billion in 2024 at a compound annual growth rate (CAGR) of 2.5%. The growth observed in the historical period can be attributed to influences stemming from environmental and lifestyle factors, historical market competition, prevailing treatment preferences in the past, economic conditions, and trends in global health history.

The anti-hypertensive drugs market size is expected to see steady growth in the next few years. It will grow to $40.28 billion in 2028 at a compound annual growth rate (CAGR) of 2.4%. The projected growth in the forecast period can be attributed to factors such as cost-effectiveness and affordability, the emergence of therapeutic innovations, trends in epidemiology, regulatory changes and approvals, dynamics related to an aging population, and shifts in healthcare policies and reimbursement structures. Key trends anticipated in the forecast period encompass therapeutic innovation, changes in epidemiological patterns, shifts in the regulatory landscape, evolving healthcare policies, and advancements in diagnosis and monitoring.

A sedentary lifestyle stands out as a significant catalyst for the expansion of the anti-hypertensive drug market. The rise in hypertension can be attributed to factors such as the consumption of unhealthy junk food, inadequate adherence to a balanced diet, and irregular sleep patterns resulting from unconventional work shifts. These lifestyle elements contribute to an upsurge in hypertension, which, in turn, serves as a major precursor for 45% of heart disease-related deaths and 51% of stroke-related fatalities. As per World Health Organization (WHO) data from June 2021, cardiovascular diseases (CVDs) claim an estimated 17.9 million lives annually, making them the leading global cause of death. This sustained demand for anti-hypertensive drugs is a key driver fostering market growth.

The escalating prevalence of cardiovascular diseases is expected to drive future growth in the anti-hypertensive drugs market. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, with risk factors including smoking, high blood pressure, high cholesterol, diabetes, obesity, and a sedentary lifestyle. Anti-hypertensive drugs play a crucial role in managing and mitigating high blood pressure, a major risk factor for cardiovascular diseases in older adults. In October 2022, the National Library of Medicine projected that by 2035, 45.1% of the US population could have cardiovascular disease, with total costs reaching $1.1 trillion. Additionally, data from the World Heart Federation in May 2023 revealed 20.5 million deaths from cardiovascular diseases in 2021. Consequently, the increasing prevalence of cardiovascular diseases is propelling the expansion of the anti-hypertensive drugs market.

One significant impediment to the anti-hypertensive drugs market is the low awareness of these medications among the population. In developing nations, many individuals neglect regular health checkups, often remaining unaware of their hypertension until severe symptoms manifest. Moreover, diagnosed individuals exhibit low adherence to prescribed medication schedules, frequently discontinuing treatment after 1-2 weeks, leading to significant challenges for the anti-hypertensive drugs market. A research survey published by BMC Research from a developing country highlighted that only 17% of 112 hypertensive subjects with stroke were adherent to antihypertensive medications. Hence, lack of awareness and poor drug adherence pose constraints to the growth of the anti-hypertensive market.

Prominent companies in the anti-hypertensive drugs market are concentrating their efforts on introducing innovative products, including Metoprolol Succinate Extended-Release Tablets, to gain a competitive advantage. Metoprolol Succinate Extended-Release Tablets serve as anti-hypertensive drugs tailored for patients with hypertension. For example, in June 2023, Granules India Limited, a pharmaceutical manufacturing company based in India, unveiled Metoprolol Succinate Extended-Release Tablets, which received approval from the US Food and Drug Administration (FDA). These tablets, available in strengths ranging from 25mg to 200mg, function as beta-blockers, slowing down the heart rate, easing the workload on the heart, and ultimately lowering blood pressure.

In recent times, there has been a notable surge in the adoption of combination therapies compared to monotherapy for hypertension treatment. While monotherapy involves using a single drug, combination therapy utilizes a mix of drugs to target various hypertensive mechanisms concurrently. Combining two drugs with distinct mechanisms of action results in an effect two to five times greater than monotherapy. Studies indicate that increasing the dose of monotherapy leads to a 29% reduction in coronary events and a 40% reduction in cerebrovascular events. In contrast, combining two antihypertensive agents with different mechanisms of action achieves a more significant impact, reducing coronary events by 40% and cerebrovascular events by 54%. Consequently, the trend of employing combination therapy is gaining widespread acceptance due to its enhanced effectiveness.

The US Food and Drug Administration (FDA) has issued guidance regarding the development of fixed-combination drugs for hypertension. This guidance primarily focuses on the clinical development of two-drug combinations comprising previously approved products. The FDA anticipates a decrease in adverse effects for combinations that include doses below each drug's maximum dose compared to single drug regimens at their maximum dose. Current medical guidelines recommend initiating patients on two drugs at less than their full doses, marking a departure from the earlier practice of starting with a single drug and titrating up to the maximum dose before introducing additional drugs. This guidance is expected to regulate the development of fixed-combination drugs for hypertension.

Major companies operating in the anti-hypertensive drugs market report are Pfizer Inc., Johnson & Johnson Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbiVe Inc., Bayer AG, Novartis AG, Sanofi SA, Astra Zeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., C.H. Boehringer Sohn AG & Ko. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Fresenius Kabi AG, Sun Pharmaceuticals LLC, Cipla Limited, Dr. Reddy's Laboratories, Hikma Pharmaceuticals PLC, Lupin Limited, United Therapeutics, Torrent Pharmaceuticals Ltd., Ranbaxy Laboratories, Noden Pharma DAC, Acacia Pharma Group PLC, Actelion Pharmaceuticals Ltd. North America was the largest region in the anti-hypertensive drugs market in 2023. The Middle East is expected to be the largest growing region in the global anti-hypertensive drugs market during the forecast period. The regions covered in the anti-hypertensive drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The key therapeutic classes of anti-hypertensive drugs include diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, alpha-blockers, calcium channel blockers, renin inhibitors, and vasodilators. Diuretics, commonly known as water pills, work by increasing the elimination of water and salt from the body through urine. Various sources of hypertension encompass primary and secondary hypertension, both of which are addressed through treatment modalities in hospitals, clinics, and home care settings.

The anti-hypertensive drugs market research report is one of a series of new reports that provides anti-hypertensive drugs market statistics, including anti-hypertensive drugs industry global market size, regional shares, competitors with an anti-hypertensive drugs market share, detailed anti-hypertensive drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-hypertensive drugs industry. This anti-hypertensive drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The countries covered in the anti-hypertensive drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-hypertensive drugs market consists of sales of thiazide-type diuretics, beta-blocker metoprolol, olmesartan, and HCTZ. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary2. Anti-Hypertensive Drugs Market Characteristics3. Anti-Hypertensive Drugs Market Trends and Strategies
4. Anti-Hypertensive Drugs Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Anti-Hypertensive Drugs Market Size and Growth
5.1. Global Anti-Hypertensive Drugs Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Anti-Hypertensive Drugs Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Anti-Hypertensive Drugs Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Anti-Hypertensive Drugs Market Segmentation
6.1. Global Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diuretics
  • Angiotensin Receptor Blockers (ARBs)
  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Beta Blockers
  • Alpha Blockers
  • Calcium Channel Blockers
  • Renin Inhibitors
  • Vasodilators
6.2. Global Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Primary Hypertension
  • Secondary Hypertension
6.3. Global Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Homecare
7. Anti-Hypertensive Drugs Market Regional and Country Analysis
7.1. Global Anti-Hypertensive Drugs Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Anti-Hypertensive Drugs Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Anti-Hypertensive Drugs Market
8.1. Asia-Pacific Anti-Hypertensive Drugs Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Anti-Hypertensive Drugs Market
9.1. China Anti-Hypertensive Drugs Market Overview
9.2. China Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Anti-Hypertensive Drugs Market
10.1. India Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Anti-Hypertensive Drugs Market
11.1. Japan Anti-Hypertensive Drugs Market Overview
11.2. Japan Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Anti-Hypertensive Drugs Market
12.1. Australia Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Anti-Hypertensive Drugs Market
13.1. Indonesia Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Anti-Hypertensive Drugs Market
14.1. South Korea Anti-Hypertensive Drugs Market Overview
14.2. South Korea Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Anti-Hypertensive Drugs Market
15.1. Western Europe Anti-Hypertensive Drugs Market Overview
15.2. Western Europe Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Anti-Hypertensive Drugs Market
16.1. UK Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Anti-Hypertensive Drugs Market
17.1. Germany Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Anti-Hypertensive Drugs Market
18.1. France Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Anti-Hypertensive Drugs Market
19.1. Italy Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Anti-Hypertensive Drugs Market
20.1. Spain Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Anti-Hypertensive Drugs Market
21.1. Eastern Europe Anti-Hypertensive Drugs Market Overview
21.2. Eastern Europe Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Anti-Hypertensive Drugs Market
22.1. Russia Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Anti-Hypertensive Drugs Market
23.1. North America Anti-Hypertensive Drugs Market Overview
23.2. North America Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Anti-Hypertensive Drugs Market
24.1. USA Anti-Hypertensive Drugs Market Overview
24.2. USA Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Anti-Hypertensive Drugs Market
25.1. Canada Anti-Hypertensive Drugs Market Overview
25.2. Canada Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Anti-Hypertensive Drugs Market
26.1. South America Anti-Hypertensive Drugs Market Overview
26.2. South America Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Anti-Hypertensive Drugs Market
27.1. Brazil Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Anti-Hypertensive Drugs Market
28.1. Middle East Anti-Hypertensive Drugs Market Overview
28.2. Middle East Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Anti-Hypertensive Drugs Market
29.1. Africa Anti-Hypertensive Drugs Market Overview
29.2. Africa Anti-Hypertensive Drugs Market, Segmentation by Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Anti-Hypertensive Drugs Market, Segmentation by Disease Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Anti-Hypertensive Drugs Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Anti-Hypertensive Drugs Market Competitive Landscape and Company Profiles
30.1. Anti-Hypertensive Drugs Market Competitive Landscape
30.2. Anti-Hypertensive Drugs Market Company Profiles
30.2.1. Pfizer Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Johnson & Johnson Ltd.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. F. Hoffmann-La Roche Ltd
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Merck & Co. Inc.
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. AbbiVe Inc.
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Anti-Hypertensive Drugs Market Other Major and Innovative Companies
31.1. Bayer AG
31.2. Novartis AG
31.3. Sanofi SA
31.4. Astra Zeneca plc
31.5. Abbott Laboratories
31.6. GlaxoSmithKline plc
31.7. Takeda Pharmaceutical Company Limited
31.8. Eli Lilly and Company
31.9. Gilead Sciences Inc.
31.10. C.H. Boehringer Sohn AG & Ko. KG
31.11. Teva Pharmaceutical Industries Ltd.
31.12. Mylan N.V.
31.13. Daiichi Sankyo Company Limited
31.14. Fresenius Kabi AG
31.15. Sun Pharmaceuticals LLC
32. Global Anti-Hypertensive Drugs Market Competitive Benchmarking33. Global Anti-Hypertensive Drugs Market Competitive Dashboard34. Key Mergers and Acquisitions in the Anti-Hypertensive Drugs Market
35. Anti-Hypertensive Drugs Market Future Outlook and Potential Analysis
35.1 Anti-Hypertensive Drugs Market in 2028 - Countries Offering Most New Opportunities
35.2 Anti-Hypertensive Drugs Market in 2028 - Segments Offering Most New Opportunities
35.3 Anti-Hypertensive Drugs Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Anti-Hypertensive Drugs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-hypertensive drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
  • Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for anti-hypertensive drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Report Scope

Markets Covered:
1) By Therapeutics: Diuretics; Angiotensin Receptor Blockers (ARBs); Angiotensin Converting Enzyme (ACE) Inhibitors; Beta Blockers; Alpha Blockers; Calcium Channel Blockers; Renin Inhibitors; Vasodilators
2) By Disease Source: Primary Hypertension; Secondary Hypertension
3) By End-users: Hospitals; Clinics; Homecare

Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson Ltd.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbiVe Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pfizer Inc.
  • Johnson & Johnson Ltd.
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • AbbiVe Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi SA
  • Astra Zeneca plc
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • C.H. Boehringer Sohn AG & Ko. KG
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Daiichi Sankyo Company Limited
  • Fresenius Kabi AG
  • Sun Pharmaceuticals LLC
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • United Therapeutics
  • Torrent Pharmaceuticals Ltd
  • Ranbaxy Laboratories
  • Noden Pharma DAC
  • Acacia Pharma Group Plc
  • Actelion Pharmaceuticals Ltd.

Methodology

Loading
LOADING...

Table Information